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Stent Implantation: Results From the NHLBI Dynamic Registry
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1University of Pittsburgh Medical Center, Pittsburgh, PA; 2Brigham and Women’s
Hospital, Boston, MA; 3University of South Florida, Tampa, FL
Background: In current practice, the duration of DAPT after BMS implantation
remains variable, and the utility of long term DAPT in patients who receive bare mental
stents remains unknown. Therefore, we sought to investigate the effect of extended
DAPT in BMS-treated patients and its effect on long term outcomes.
Methods: We analyzed data from consecutive patients who received bare metal stents
enrolled in Waves 4(2004) and 5(2006) of the NHLBI Dynamic Registry. Those
patients who remained event free during the first year of follow up were stratified
according to whether they were on DAPT at one year after stent implantation or not,
and a landmark analysis was performed. Patients were followed for up to four years
for the occurrence of cardiovascular events and death.
Results: A total of 526 patients with a mean age of 64 years were evaluated for the
12-month landmark, with 310 (59%) on DAPT at one year. There were no significant
differences in baseline characteristics between the two groups. In the landmark
analysis, there was a significantly lower 4-year rate of death in the group that continued
DAPT compared to the group that did not (Figure 1: 8.5% vs. 14.3%, p = 0.03).
Beneficial differences were preserved after multivariate and propensity adjustment.
Death Rates for BMS patients Event Free at One Year by Dual Anti-Platelet Therapy
Use
Conclusion: Following BMS implantation, those who remain on DAPT for at least
one year appear to have improved survival compared those who do not. These findings
suggest that extended use of Clopidogrel up to one year might be considered in those
who receive BMS, and do not otherwise have contraindications to longer term DAPT.
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Background: In certain high-risk groups, such as patients undergoing saphenous vein
graft PCI, the association between clopidogrel duration and adverse cardiovascular
events has not been reported.
Methods: We identified consecutive patients undergoing saphenous vein graft PCI
between 2000-2009 in an integrated prepaid health care system. Clopidogrel utilization
was ascertained from pharmacy records. The date of the prescription and quantity of
tablets dispensed were recorded for every clopidogrel prescription filled by the patient
post-PCI. A multivariable logistic regression model was used to generate predicted
probabilities for all-cause mortality and myocardial infarction (MI) post-PCI. The
model was adjusted for age, gender, diabetes, hypertension, other comorbidities, stent
type, clopidogrel noncompliance, and use of cardioprotective medications.
Results: There were 576 patients who underwent saphenous vein graft PCI during the
study period. The mean age was 68 ± 10 years and 18% were female. The median
follow-up was 3-years. Longer duration of clopidogrel therapy was associated with a
lower predicted probability of death or MI post-PCI (see figure). There does not appear
to be a threshold effect after which continued clopidogrel therapy is no longer effective.
Conclusion: This is the first report, to our knowledge, to characterize the relationship
between duration of clopidogrel therapy and long-term adverse cardiovascular
outcomes after saphenous vein graft PCI. These data suggest that longer duration of
dual antiplatelet therapy with clopidogrel is associated with a significant reduction in
death and MI in this high-risk group.
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Background: The aim of the current study was to perform two separate meta-analyses
of available studies comparing low-molecular-weight heparins (LMWHs) versus
unfractionated heparin (UFH) in ST-elevation myocardial infarction (STEMI) patients
treated 1) with primary percutaneous coronary intervention (pPCI) or 2) with PCI after
thrombolysis.
Methods: All-cause mortality was the prespecified primary endpoint and major
bleeding complications were recorded as secondary endpoint. Relative risk (RR) with
95 % confidence interval (CI) and absolute risk reduction (ARR) were chosen as the
effect measure.
Results: Ten studies comprising 16286 patients were included. The median follow-up
was two months for the primary endpoint. Among LMWHs, enoxaparin was the
compound most frequently used. In the pPCI group LMWHs were associated with a
reduction in mortality (RR [95% CI] = 0.51 [0.41 - 0.64], p < 0.001, ARR = 3%) and
major bleeding (RR [95% CI] = 0.68 [0.49 - 0.94], p = 0.02, ARR = 2.0 %) as compared
to UFH. Conversely, no clear evidence of benefits with LWMHs was observed in the
PCI group after thrombolysis. Meta-regression showed that patients with higher
baseline risk had larger benefits from LMWHs (r = 0.72, p = 0.02).
Conclusion: LMWHs were associated with greater efficacy and safety than UFH in
STEMI patients treated with pPCI, with a significant relationship between risk profile
and clinical benefits. Based on this meta-analysis, LMWHs may be considered as a
preferred anticoagulant among STEMI patients undergoing pPCI.
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Evaluation of Dose Requirements for Prolonged Bivalirudin Administration in
Patients with Renal Insufficiency and Suspected Heparin-Induced
Thrombocytopenia
James W Wisler1, Jeffrey B Washam2, Richard C Becker1, 3
1Duke University Medical Center, Durham, NC; 2Duke Heart Center, Durham, NC;
3Duke Clinical Research Institute, Durham, NC
Background: Bivalirudin is indicated for patients with suspected heparin-induced
thrombocytopenia (HIT) and anticipated percutaneous coronary intervention. There
are limited data on dose selection among patients with renal insufficiency, particularly
when clinical conditions dictate a prolonged infusion (>24h).
Methods: The study cohort comprised 73 patients with renal dysfunction who received
bivalirudin for suspected HIT with or without acute coronary syndrome. We reviewed
individual pharmacy and medical records for laboratory and bivalirudin dosing
information, medical co-morbidities, and adverse clinical outcomes during
administration.
Results: Average duration of treatment was 10.2 ± 11.6 days. When estimated
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